Combined effect of furanone fluconazole and amphotericin B against biofilms formed from Cryptococcus neoformans

Kirthniamoorthy Meenakumari¹ & Giridharan Bupesh¹,²*

¹Research & Development Wing, Sree Balaji Medical College and Hospital (SBMCH), Bharath University, BIHER, Chrompet, Chennai 600044, Tamil Nadu, India; ²Department of Forest Science, Central University of Nagaland, Lumami, India; *Corresponding author: Dr. Giridharan Bupesh - Email: bupeshgiri55@gmail.com

Received January 15, 2021; Revised April 25, 2021; Accepted May 6, 2021, Published May 31, 2021

DOI: 10.6026/97320630017536

Declaration on official E-mail:
The corresponding author declares that official e-mail from their institution is not available for all authors

Declaration on Publication Ethics:
The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Abstract:
It is of interest to document the combined effect of furanone fluconazole and amphotericin B against the biofilm formed by Cryptococcus neoformans. The MIC values of amphotericine B and Fluconazole were observed as 20µg/ml and 60µg/ml, respectively. The MIC for the Combination (Amphotericin B/Fluconazole) was found to be at (15/20) µg/ml drug concentration. Thus, data shows the combined effect of furanone fluconazole and amphotericine B derivative against C. neoformans.

Keywords: Cryptococcus neoformans, fluconazole, amphotericin B, biofilm

Background:
Cryptococcus neoformans are the encapsulated fungus groups that cause meningoencephalitis in immuno-compromised individuals [1, 3]. Cryptococcal spores and/or dried yeast cells are very small in size and can deposit deep in the respiratory tract following inhalation [2]. Amphotericin B is an antifungal drug given intravenously for serious fungal infections. Amphotericin B is effective with side effects to lungs and kidneys [4-10]. Polysaccharide capsule of C. neoformans enlarge the size of capsule during infection and the mechanism of growth was unknown [11-13]. Therefore, it is of interest to document the combined effect of furanone fluconazole and amphotericin B against the biofilm formed by Cryptococcus neoformans.

Materials and Method:
C. neoformans strain ATCC 14116 (isolated from pigeon dropping contaminated soil) was maintained in Potato Dextrose Agar (PDA) (Himedia-M096) slants and Potato Dextrose Broth (PDB) (Himedia-M403). This was inoculated at 37°C for 48 hours.
Preparation of drug stock solutions:
20mg of amphotericin B and 20mg of fluconazole was weighted and dissolved in 1ml of Dimethyl sulfoxide (DMSO) and stored at 2°C in vials. Drug stock solution was diluted according to the culture and the DMSO concentration was equally maintained in all experiments (<1%) as shown in Table 1.

| Treatment          | Experimental type | Drug  | Working stock (µg/ml of DMSO) |
|--------------------|-------------------|-------|-------------------------------|
| Individual drug    | Biofilm           | AMPB  | 20µg/ml                        |
|                    | Biofilm           | FLC   | 100µg/ml                       |
| Combinational drug | Biofilm           | AMPB  | 40µg/ml                        |
|                    | Biofilm           | FLC   | 200µg/ml                       |

Figure 1: Fluorescent microscopy image of untreated melanized C. neoformans (ATCC strain) biofilm

**Individual drug Treatment:**
The MIC of antifungal drugs against C. neoformans biofilm is inoculated in a 96-well plate along with positive and negative control. This was incubated at 37°C for 7days. The 96 well plates are washed twice with Phosphate Buffer Saline (PBS) to remove free-living cells from the plate after the biofilm formation. Drugs were then added into the wells and incubated at 37°C for 48 hours. This was washed twice with PBS and the absorbance was measured using ELISA plate reader at 620nm.

Figure 2: Fluorescent microscopy image of the combined treatment of melanized C. neoformans biofilm with the concentration of Amphotericin B and Fluconazole (15/20µg/ml)

Figure 3: Fluorescent microscopy image of the combined treatment of melanized C. neoformans biofilm with the concentration of Amphotericin B and Fluconazole (17.5/20µg/ml)
**Combined drug treatment:**
Two fold dilution method of the drug both above and below the MIC value were prepared. The individual MIC value of amphotericin B and Fluconazole is shown in Table 2. The antifungal drugs were serially diluted. Equal volume of inoculums was added using the Checkerboard method. The culture were added equally to the all wells and incubated at 37°C for 48 hours.

| Strain   | Drugs       | Biofilm |
|----------|-------------|---------|
| ATCC 14116 | Amphotericin B, Fluconazole | 20µg/ml, 60µg/ml |

**Concentration of amphotericin B (µg/ml):**
Amphotericin B was added in the concentration range of 0-5µg/ml. Fluconazole was added in the range of 0-25µg/ml. The plates are then incubated at 37°C for 48 hours. The incubation plates are washed twice with phosphate buffer saline (PBS) and the absorbance was measured using a ELISA plate reader at 620nm (Automatic ELISA Reader - Sunrise)

**Fluorescent Microscopy:**
The cell were washed twice with PBS, the cells were stained with FITC and propidium iodine that were prepared at the concentration of 30µg/ml respectively. The staining solutions were added and let to standing for 15min in dark. The staining solution was removed and washed with PBS. The samples were then analyzed using a Nikon Trinocular microscope (Nikon Eclipse Ni-U Japan) [14].

**Results & Discussion:**
The concentration range of Amphotericin B and Fluconazole used for ATCC strain was 16µg/ml to 240µg/ml and 60µg/ml to 100µg/ml. The MIC value was found to be 25/15 µg/ml (Amphotericin B/Fluconazole) (Figure 1). The MIC value in combination is slightly higher or equal to the individual drug MIC value. The concentration of Amphotericin B increased. This may be because of the resistance shown by the organism towards the single drug. MIC of amphotericin B and fluconazole were found to be 20µg/ml and 60µg/ml respectively. The MIC for the combination (amphotericin B/fluconazole) was found to be at (15/20) µg/ml drug concentration. The control of both the strains showing green fluorescent indicating live cells as shown in Figure 2 to 4. It was observed that the combination drug treatment is capable of disrupting the biofilm with killing the cells as well as disintegrate the biofilm. Biofilm formation has an important role for the *C. neoformans* to survive within the macrophages and to colonize in the central nervous system (CNS) [13]. Thus, disrupting the biofilm help to reducing the virulence nature to control the pathogen at the site of infection [16-17].

**Conclusion:**
The data shows the combined effect of furanone fluconazole and amphotericine B derivative against *C. neoformans* by disrupting the formation of biofilms.

**References:**
[1] Martinez LR, Casadevall A. Appl. Environ. Microbial. 2007; 73:4592-4601. [PMID: 17513597].
[2] Ravi S, et al. Mycopathologia 2009; 167:307-314. [PMID: 19130292].
[3] Martinez LR, et al. J Infect Dis. 2006; 194(2): 261-6. [PMID: 16779734].
[4] Braun DK, et al. Am J Kidney Dis. 1994; 24(5): 864-7. [PMID: 7977331].
[5] Casadevall A, et al. Curr Opin Microbial. 2003; 6(4): 332-7. [PMID: 12941400].
[6] Joubert LM, et al. Microb Ecol. 2006; 52(2): 187-97. [PMID: 16897306].
[7] Fisher RS, Bonner AM. The Neurodiagnostic Journal. 2018; 58:1. [PMID: 29562876].
[8] Donlan, RM, Costerton, JW. Clin Microbiol Rev. 2002; 15: 167-193. [PMID: 11932229].

![Fluorescent Microscopy Image](image-url)
[9] Toossi H, et al. Brain Structure and Function. 2017; 222:3163. [PMID: 28299422].
[10] Xiaojun Xu, et a. Biochemical and biophysical research communications. 2016; 473:795. [PMID: 27049309].
[11] Walsh TJ, et al. Neurosurgery. 1986 Mar; 18(3): 373-5. [PMID: 3517675].
[12] Steenbergen JN, et al. Proc. Natl. Acad. Sci. USA 2001; 98:15245–15250. [PMID: 11742090].
[13] Sethuramanujam S, et al. Neuron. 2016; 90:1243. [PMID: 27238865].
[14] Viereck MJ, et al. J Clin Neurosci. 2014;(11): 2020-1. [PMID: 25220283].
[15] Ingram CW, et al. Infect Control Hosp Epidemiol. 1993; 14(12): 719-22. [PMID: 8132998]
[16] Kotob SI, et al. Appl Environ Microbiol. 1995; 61:1620-2. [PMID: 7747976]
[17] Greer ND. In Baylor University Medical Center Proceedings 2003; 16,241-248. [PMID: 32398486]

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words.
